Literature DB >> 33551812

Cellular Uptake of Psychostimulants - Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?

Ole Jensen1, Muhammad Rafehi1, Lukas Gebauer1, Jürgen Brockmöller1.   

Abstract

Psychostimulants are used therapeutically and for illegal recreational purposes. Many of these are inhibitors of the presynaptic noradrenaline, dopamine, and serotonin transporters (NET, DAT, and SERT). According to their physicochemical properties, some might also be substrates of polyspecific organic cation transporters (OCTs) that mediate uptake in liver and kidneys for metabolism and excretion. OCT1 is genetically highly polymorphic, with strong effects on transporter activity and expression. To study potential interindividual differences in their pharmacokinetics, 18 psychostimulants and hallucinogens were assessed in vitro for transport by different OCTs as well as by the high-affinity monoamine transporters NET, DAT, and SERT. The hallucinogenic natural compound mescaline was found to be strongly transported by wild-type OCT1 with a K m of 24.3 µM and a v max of 642 pmol × mg protein-1 × min-1. Transport was modestly reduced in variants *2 and *7, more strongly reduced in *3 and *4, and lowest in *5 and *6, while *8 showed a moderately increased transport capacity. The other phenylethylamine derivatives methamphetamine, para-methoxymethamphetamine, (-)-ephedrine, and cathine ((+)-norpseudoephedrine), as well as dimethyltryptamine, were substrates of OCT2 with K m values in the range of 7.9-46.0 µM and v max values between 70.7 and 570 pmol × mg protein-1 × min-1. Affinities were similar or modestly reduced and the transport capacities were reduced down to half in the naturally occurring variant A270S. Cathine was found to be a substrate for NET and DAT, with the Km being 21-fold and the v max 10-fold higher for DAT but still significantly lower compared to OCT2. This study has shown that several psychostimulants and hallucinogens are substrates for OCTs. Given the extensive cellular uptake of mescaline by the genetically highly polymorphic OCT1, strong interindividual variation in the pharmacokinetics of mescaline might be possible, which could be a reason for highly variable adverse reactions. The involvement of the polymorphic OCT2 in the renal excretion of several psychostimulants could be one reason for individual differences in toxicity.
Copyright © 2021 Jensen, Rafehi, Gebauer and Brockmöller.

Entities:  

Keywords:  OCT1; SLC22A1; hallucinogen; membrane transport; monoamine transporter; organic cation transporter; psychostimulant; solute carrier

Year:  2021        PMID: 33551812      PMCID: PMC7854383          DOI: 10.3389/fphar.2020.609811

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  73 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.

Authors:  Pieter J Hoekstra; Pieter W Troost; Bertine E Lahuis; Hans Mulder; Erik J Mulder; Barbara Franke; Jan K Buitelaar; George M Anderson; Lawrence Scahill; Ruud B Minderaa
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

Review 3.  The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective.

Authors:  Tai Rao; Zhirong Tan; Jingbo Peng; Ying Guo; Yao Chen; Honghao Zhou; Dongsheng Ouyang
Journal:  Pharmacol Res       Date:  2019-05-23       Impact factor: 7.658

Review 4.  Bioactive compounds and health benefits of Pereskioideae and Cactoideae: A review.

Authors:  Tânia da Silveira Agostini-Costa
Journal:  Food Chem       Date:  2020-04-30       Impact factor: 7.514

5.  Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.

Authors:  Mladen V Tzvetkov; Johannes Matthaei; Sherin Pojar; Frank Faltraco; Sabrina Vogler; Thomas Prukop; Tina Seitz; Jürgen Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2017-12-08       Impact factor: 6.875

6.  Predicting new molecular targets for known drugs.

Authors:  Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian K Shoichet; Bryan L Roth
Journal:  Nature       Date:  2009-11-01       Impact factor: 49.962

7.  Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice.

Authors:  Vincent Vialou; Laure Balasse; Jacques Callebert; Jean-Marie Launay; Bruno Giros; Sophie Gautron
Journal:  J Neurochem       Date:  2008-05-30       Impact factor: 5.372

8.  Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.

Authors:  D Gründemann; S Köster; N Kiefer; T Breidert; M Engelhardt; F Spitzenberger; N Obermüller; E Schömig
Journal:  J Biol Chem       Date:  1998-11-20       Impact factor: 5.157

Review 9.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  An unsuspected role for organic cation transporter 3 in the actions of amphetamine.

Authors:  Felix P Mayer; Diethart Schmid; W Anthony Owens; Georgianna G Gould; Mia Apuschkin; Oliver Kudlacek; Isabella Salzer; Stefan Boehm; Peter Chiba; Piper H Williams; Hsiao-Huei Wu; Ulrik Gether; Wouter Koek; Lynette C Daws; Harald H Sitte
Journal:  Neuropsychopharmacology       Date:  2018-04-06       Impact factor: 8.294

View more
  3 in total

1.  Overlap and Specificity in the Substrate Spectra of Human Monoamine Transporters and Organic Cation Transporters 1, 2, and 3.

Authors:  Lukas Gebauer; Ole Jensen; Maria Neif; Jürgen Brockmöller; Christof Dücker
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

2.  Relationships between Inhibition, Transport and Enhanced Transport via the Organic Cation Transporter 1.

Authors:  Ole Jensen; Lukas Gebauer; Jürgen Brockmöller; Christof Dücker
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

3.  Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.

Authors:  Thomas J F Angenoorth; Stevan Stankovic; Marco Niello; Marion Holy; Simon D Brandt; Harald H Sitte; Julian Maier
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.